Moleculin Biotech announced it has finalized enrollment in the Part A of its Phase 2/3 MIRACLE trial for Annamycin. This achievement positions the company to report pivotal efficacy data on the treatment for relapsed or refractory acute myeloid leukemia in Q1 2027.